AnaptysBio Financial Statements (ANAB)
|
|
|
|
Report date
|
|
|
02.03.2020 |
25.02.2021 |
07.03.2022 |
01.03.2023 |
11.03.2024 |
|
05.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
8.00 |
75.0 |
63.2 |
10.3 |
17.2 |
|
57.2 |
|
Operating Income, bln rub |
|
|
-107.4 |
-23.9 |
-56.8 |
-115.2 |
-164.4 |
|
-147.4 |
|
EBITDA, bln rub |
? |
|
-95.9 |
-19.4 |
-55.7 |
-105.3 |
-143.2 |
|
-125.6 |
|
Net profit, bln rub |
? |
|
-97.3 |
-19.9 |
-57.2 |
-128.7 |
-163.6 |
|
-165.7 |
|
|
OCF, bln rub |
? |
|
-69.5 |
-14.2 |
-45.9 |
-73.6 |
-120.8 |
|
-103.0 |
|
CAPEX, bln rub |
? |
|
0.805 |
0.569 |
1.37 |
0.358 |
0.807 |
|
0.375 |
|
FCF, bln rub |
? |
|
-70.3 |
-14.7 |
-47.3 |
-74.0 |
-121.6 |
|
-103.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
115.4 |
98.9 |
120.0 |
125.4 |
181.6 |
|
196.0 |
|
Cost of production, bln rub |
|
|
99.3 |
80.0 |
98.5 |
2.34 |
2.38 |
|
2.40 |
|
R&D, bln rub |
|
|
99.3 |
80.0 |
98.5 |
88.8 |
132.3 |
|
154.5 |
|
Interest expenses, bln rub |
|
|
1.04 |
0.000 |
1.45 |
21.1 |
18.1 |
|
37.6 |
|
|
Assets, bln rub |
|
|
435.2 |
416.6 |
643.1 |
610.4 |
452.4 |
|
493.4 |
|
Net Assets, bln rub |
? |
|
405.0 |
396.7 |
356.4 |
262.1 |
88.1 |
|
84.4 |
|
Debt, bln rub |
|
|
2.25 |
0.342 |
21.0 |
19.5 |
17.8 |
|
16.5 |
|
Cash, bln rub |
|
|
374.2 |
393.7 |
548.1 |
441.2 |
390.9 |
|
430.1 |
|
Net debt, bln rub |
|
|
-372.0 |
-393.3 |
-527.1 |
-421.8 |
-373.1 |
|
-413.6 |
|
|
Ordinary share price, rub |
|
|
16.3 |
21.5 |
34.8 |
31.0 |
21.4 |
|
16.2 |
|
Number of ordinary shares, mln |
|
|
27.1 |
27.3 |
27.4 |
28.2 |
26.9 |
|
28.9 |
|
|
Market cap, bln rub |
|
|
440 |
587 |
953 |
873 |
577 |
|
467 |
|
EV, bln rub |
? |
|
68 |
194 |
426 |
451 |
204 |
|
54 |
|
Book value, bln rub |
|
|
405 |
397 |
356 |
262 |
88 |
|
84 |
|
|
EPS, rub |
? |
|
-3.60 |
-0.73 |
-2.08 |
-4.57 |
-6.08 |
|
-5.73 |
|
FCF/share, rub |
|
|
-2.60 |
-0.54 |
-1.72 |
-2.63 |
-4.52 |
|
-3.58 |
|
BV/share, rub |
|
|
15.0 |
14.5 |
13.0 |
9.31 |
3.27 |
|
2.92 |
|
|
EBITDA margin, % |
? |
|
-1 199% |
-25.8% |
-88.2% |
-1 023% |
-834.4% |
|
-219.7% |
|
Net margin, % |
? |
|
-1 217% |
-26.6% |
-90.5% |
-1 251% |
-953.7% |
|
-289.8% |
|
FCF yield, % |
? |
|
-16.0% |
-2.51% |
-4.96% |
-8.47% |
-21.1% |
|
-22.1% |
|
ROE, % |
? |
|
-24.0% |
-5.02% |
-16.0% |
-49.1% |
-185.7% |
|
-196.4% |
|
ROA, % |
? |
|
-22.4% |
-4.78% |
-8.89% |
-21.1% |
-36.2% |
|
-33.6% |
|
|
P/E |
? |
|
-4.52 |
-29.5 |
-16.7 |
-6.78 |
-3.52 |
|
-2.82 |
|
P/FCF |
|
|
-6.25 |
-39.9 |
-20.2 |
-11.8 |
-4.74 |
|
-4.52 |
|
P/S |
? |
|
55.0 |
7.83 |
15.1 |
84.8 |
33.6 |
|
8.18 |
|
P/BV |
? |
|
1.09 |
1.48 |
2.67 |
3.33 |
6.55 |
|
5.54 |
|
EV/EBITDA |
? |
|
-0.71 |
-10.00 |
-7.65 |
-4.29 |
-1.42 |
|
-0.43 |
|
Debt/EBITDA |
|
|
3.88 |
20.3 |
9.46 |
4.01 |
2.61 |
|
3.29 |
|
|
R&D/CAPEX, % |
|
|
12 340% |
14 064% |
7 211% |
24 804% |
16 392% |
|
41 189% |
|
|
CAPEX/Revenue, % |
|
|
10.1% |
0.76% |
2.16% |
3.48% |
4.70% |
|
0.66% |
|
| AnaptysBio shareholders |
